GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA en liquidation (OTCPK:ELVYY) » Definitions » 5-Year EBITDA Growth Rate

Evolva Holding en liquidation (Evolva Holding en liquidation) 5-Year EBITDA Growth Rate : 11.10% (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Evolva Holding en liquidation 5-Year EBITDA Growth Rate?

Evolva Holding en liquidation's EBITDA per Share for the six months ended in Jun. 2023 was $-185.16.

During the past 3 years, the average EBITDA Per Share Growth Rate was -23.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Evolva Holding en liquidation was 72.00% per year. The lowest was -23.50% per year. And the median was 20.90% per year.


Competitive Comparison of Evolva Holding en liquidation's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Evolva Holding en liquidation's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolva Holding en liquidation's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolva Holding en liquidation's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Evolva Holding en liquidation's 5-Year EBITDA Growth Rate falls into.



Evolva Holding en liquidation 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Evolva Holding en liquidation  (OTCPK:ELVYY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Evolva Holding en liquidation 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Evolva Holding en liquidation's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolva Holding en liquidation (Evolva Holding en liquidation) Business Description

Traded in Other Exchanges
Address
Duggingerstrasse 23, Reinach, CHE, CH-4153
Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.

Evolva Holding en liquidation (Evolva Holding en liquidation) Headlines

From GuruFocus

Half Year 2023 Evolva Holding SA Earnings Call Transcript

By GuruFocus Research 02-13-2024